论文部分内容阅读
目的评价莫西沙星短程治疗社区获得性肺炎(CAP)的疗效及安全性。方法87例轻中度CAP患者随机分为两组。对照组(传统疗程组)予莫西沙星静脉治疗10 d;短程治疗组予莫西沙星静脉治疗5 d。结果①对照组和短程治疗组痊愈率分别为68.2%(30/44)和65.1%(28/43),临床有效率分别为90.9%(40/44)和88.4%(38/43),细菌清除率分别为88.2%(30/34)和87.9%(29/33);这三个指标中,两组间比较差异均无统计学意义。②对照组和短程治疗组不良反应发生率分别为9.1%(4/44)和7.0%(3/43),两组间比较差异无统计学意义。结论莫西沙星短程治疗社区获得性肺炎效果与莫西沙星传统疗程治疗相似,较安全。
Objective To evaluate the efficacy and safety of moxifloxacin in the treatment of community-acquired pneumonia (CAP). Methods 87 patients with mild to moderate CAP were randomly divided into two groups. The control group (conventional treatment group) was treated with moxifloxacin for 10 days, while the short-term treatment group was given moxifloxacin for 5 days. Results The cure rates of control group and short-term treatment group were 68.2% (30/44) and 65.1% (28/43), respectively. The clinical effective rates were 90.9% (40/44) and 88.4% (38/43) respectively. The clearance rate was 88.2% (30/34) and 87.9% (29/33) respectively. There was no significant difference between the two groups in the three indexes. The incidence of adverse reactions in the control group and the short-term treatment group were 9.1% (4/44) and 7.0% (3/43) respectively, with no significant difference between the two groups. Conclusion Moxifloxacin short-course treatment of community-acquired pneumonia is similar to the traditional treatment of moxifloxacin, safer.